乐普医疗(300003.SZ)子公司拟将MWN105注射液有偿许可给丹麦Sidera

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotech, has granted a paid license for the MWN105 injection to Danish company Sidera, which will have exclusive rights to develop and commercialize the product outside of Greater China [1] Group 1: Licensing Agreement - Shanghai Minwei Biotech will receive a 9.99% equity stake in Sidera as part of the licensing agreement [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million [1] - Sidera will pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1] Group 2: Revenue Sharing - Shanghai Minwei Biotech has the right to receive a tiered sales commission from Sidera based on actual annual net sales, excluding Greater China [1]